Hamed Javan MD

Jewish General Hospital

Dr Javan is a medical doctor, completed Master of Experimental Medicine-Oncology program at McGill University, and working as clinical/research at the Jewish General Hospital with Dr Petr Kavan and Dr Gerald Batist. Dr Javan has established a phase II clinical trial for pancreatic cancer. He has a high interest toward investigator-initiated studies, and running new study protocols. Currently, he is preparing new studies in phase II, III and IV for Pancreatic and Colorectal Cancer. His particular research interest is: Pre—operative FOLFIRINOX in pancreatic cancer.

dont miss

Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer

Pancreatic Cancer is a disease with poor prognosis. In 2017, its 5-year net survival rate is only 8% with only 2% in metastatic setting and it is third common cause of cancer related death. Only less than 20% of cases are eligible for surgery at diagnosis, so we tried to evaluate the role preoperative FOLFIRINOX in potentially curable pancreatic cancer in retrospective study and clinical trial.

EVEN MORE SEMINARS

  • Prantik Das: Speaking at the Oncology Convention

    Prantik Das
    University Hospital of Derby and Burton NHS Foundation Trust

    The Changing Landscape of Prostate Radiotherapy

  • Dr Abeer Shabaan: Speaking at the Oncology Convention

    Dr Abeer Shabaan
    Queen Elizabeth Hospital Birmingham & University of Birmingham

    Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations

  • Dr Penny Kechagioglou: Speaking at the Oncology Convention

    Dr Penny Kechagioglou
    GenesisCare UK

    Breast cancer Service of the Future: a service transformation

  • Professor Robert Thomas: Speaking at the Oncology Convention

    Professor Robert Thomas
    Bedford and Addenbrooke's Cambridge University Hospitals

    Evidence based lifestyle strategies after cancer - a research review

  • Professor Anthony Howell: Speaking at the Oncology Convention

    Professor Anthony Howell
    The University of Manchester / The Christie NHS Foundation Trust

    Improving risk estimation of breast cancer